Investment analysts at StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Trading Down 5.8 %
Shares of NASDAQ:GLMD opened at $3.87 on Friday. The business has a fifty day simple moving average of $3.60 and a 200 day simple moving average of $4.05. Galmed Pharmaceuticals has a 1 year low of $2.73 and a 1 year high of $10.50. The firm has a market cap of $2.48 million, a price-to-earnings ratio of -1.61 and a beta of 0.67.
About Galmed Pharmaceuticals
Recommended Stories
- Five stocks we like better than Galmed Pharmaceuticals
- High Flyers: 3 Natural Gas Stocks for March 2022
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Comparing and Trading High PE Ratio Stocks
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- Election Stocks: How Elections Affect the Stock Market
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.